Understanding how p53 prevents benign tumors from becoming malignant
Official title: Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
Funded at Sloan-Kettering Inst Can Research · NIH-10880603 · Data updated 2026-11-12
This study is looking at how a protein called p53 helps stop early tumors from turning into cancer, especially in a tough type of cancer called pancreatic ductal carcinoma, to find new ways to prevent and treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 3, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $697,824 |
| NIH project number | 5R01CA283378-02 |
| Project ID | NIH-10880603 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with early-stage tumors or those at high risk for developing pancreatic ductal carcinoma.
✕Less likely to help
Patients with advanced-stage cancers or those without any tumor presence may not benefit from this research.
What this research studies
This research investigates the role of the p53 protein, a key tumor suppressor, in preventing the progression of benign tumors to malignant cancers. By examining the mechanisms that activate p53 and its functions in cellular processes, the study aims to uncover how p53 can stop cells with early signs of cancer from becoming fully malignant. The research focuses specifically on pancreatic ductal carcinoma, a particularly aggressive form of cancer, to identify critical events that occur when p53 is lost. This could lead to new strategies for cancer prevention and treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for preventing the progression of benign tumors to malignant cancers, potentially saving lives.
How similar studies have gone: Previous research has shown promising results in understanding the role of p53 in tumor suppression, indicating that this approach has potential for significant breakthroughs.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Lowe, Scott W. — Sloan-Kettering Inst Can Research
- Study coordinator: Lowe, Scott W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.